Search results for "Cardiovascular prevention"

showing 10 items of 25 documents

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European…

2016

AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% female…

EUROASPIRE InvestigatorsMaleCardiac & Cardiovascular SystemsTime FactorsEpidemiologyCARDIOVASCULAR-DISEASE PREVENTIONCoronary DiseaseComorbidity030204 cardiovascular system & hematologyOverweightlaw.invention0302 clinical medicineRandomized controlled triallawRisk FactorsPrevalenceSecondary PreventionARTERY-DISEASE030212 general & internal medicineEUROASPIREguidelinesProspective StudiesPractice Patterns Physicians'Societies MedicalSecondary preventionGLUCOSE REGULATIONSmokingcardiovascular preventionRANDOMIZED CONTROLLED-TRIALMiddle AgedClinical PracticeEuropeTreatment OutcomePractice Guidelines as TopicCardiologyLDL Cholesterol LipoproteinsFemaleGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentCardiologyHEART-DISEASERisk Assessmentrehabilitation03 medical and health sciencesYoung AdultCardiovascular preventionSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansRisk factorCARDIAC REHABILITATIONExerciseAgedScience & TechnologyTask forcebusiness.industryCardiovascular AgentsDietCross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEHealth Care SurveysCardiovascular System & CardiologySmoking CessationSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCEEuropean journal of preventive cardiology
researchProduct

The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study

2021

Objectives: In older individuals, the role of serum uric acid (SUA) as risk factor for mortality is debated. This study investigated the association of SUA with all-cause and cardiovascular (CV) mortality in older adults participating in the large multicentre observational uric acid right for heart health (URRAH) study. Methods: Eight thousand URRAH participants aged 65+ were included in the analysis. The predictive role of SUA was assessed using Cox regression models stratified according to the cut-off age of 75. SUA was tested as continuous and categorical variable (age-specific quartiles). The prognostic threshold of SUA for mortality was analysed using receiver operating characteristic …

Settore MED/09 - Medicina InternahypertensionPhysiologyAged; Humans; Prognosis; Proportional Hazards Models; Risk Factors; Uric Aciduric acid; hypertension; elderly; cardiovascular prevention; stroke; myocardial infarctionAcid Urc mortality old agePrognosisCardiovascular riskelderlystrokeolder adultCardiovascular preventionmyocardial infarctionRisk FactorsOlder adultsCardiovascular prevention; Cardiovascular risk; Mortality; Older adults; Uric acidInternal MedicineHumansMortalityCardiology and Cardiovascular MedicineUric acidAgedProportional Hazards Models
researchProduct

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

2022

AimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverseevents. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have beenused to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulnessof the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Associ-ation (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular riskin CML patients, compared with SCORE risk charts. The secondary aim was to establish…

AdultHeart FailureMaleAspirinMiddle AgedRisk AssessmentCardio-oncology Cardiovascular prevention Chronic myeloid leukaemia Nilotinib Ponatinib Cardiovascular toxicityCardiotoxicityInducible T-Cell Co-Stimulator ProteinLeukemia Myelogenous Chronic BCR-ABL PositiveChronic DiseaseHumansFemaleCardiology and Cardiovascular MedicineAgedRetrospective StudiesESC Heart Failure
researchProduct

Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain

2020

Background: Cardiovascular prevention and rehabilitation programmes (CVPRP) are an established model of care designed to improve risk factor management. They have been successfully implemented in a variety of settings, in patients with coronary heart disease (CHD). Objective: To assess the long term impact of a nurse-coordinated, multidisciplinary, CVPRP in patients with CHD in the reduction of lipid profile and medication prescription in clinical practice. Methods: The study used an analytical, experimental, population based, prospective and longitudinal design. In Spain, the study was conducted in the Valencian Community, including two randomized hospitals. Coronary patients were prospec…

Malemedicine.medical_specialtyCardiotonic AgentsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentNurse's RoleMedication prescriptionCardiovascular preventionIntervention (counseling)HumansImmunology and AllergyMedicineLongitudinal StudiesProspective StudiesMedical prescriptionHealth policyAgedRehabilitationmedicine.diagnostic_testbusiness.industryMiddle AgedLipidsCoronary heart diseaseEuropePrimary PreventionCardiovascular DiseasesSpainEmergency medicineFemaleDiet HealthyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profileRisk Reduction BehaviorEndocrine, Metabolic &amp; Immune Disorders - Drug Targets
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct

Cardiovascular prevention and at-risk behaviours in a large population of amateur rugby players.

2019

Background and aim We aimed to investigate cardiovascular risk factors and health behaviours prospectively in a large population of French amateur rugby players. Methods An anonymous questionnaire was displayed to rugby players aged over 12 years enrolled in the 2014–2015 French amateur rugby championship from the Burgundy region ( n = 5140). Questions addressed awareness on: (a) cardiovascular prevention; (b) tobacco, alcohol and highly caffeinated beverages consumption; and (c) adherence to prevention guidelines (ECG checks, training in basic life support, avoidance of sports practice during fever/infectious episodes). Results Among the 640 participants who completed the questionnaires, m…

AdultMaleHealth Knowledge Attitudes PracticeAdolescentAlcohol DrinkingFeverEpidemiologyCardiovascular risk factorsHealth BehaviorLarge populationFootball030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesElectrocardiographyYoung Adult0302 clinical medicineCardiovascular preventionRisk FactorsEnvironmental healthCaffeineMedicineHumansProspective StudiesChildLife StyleAgedbusiness.industrySmoking030229 sport sciencesMiddle AgedProtective FactorsAthletesCardiovascular DiseasesFemaleFranceCardiology and Cardiovascular MedicinebusinessAmateurRisk Reduction BehaviorEuropean journal of preventive cardiology
researchProduct

Low-density-lipoproteins size and cardiovascular prevention

2005

Low-density lipoprotein (LDL) size appears to be an important predictor of cardiovascular events and progression of coronary artery disease, and the predominance of small, dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Yet, other authors have suggested that LDL subclass measurement does not add independent information to that conferred generically by LDL concentration and other standard risk factors. Therefore, the debate continues as to whether to measure LDL particle size for cardiovascular prevention and, if so, in which categories of patients. Since the therapeutic modulation of distinct LDL …

Small dense ldlmedicine.medical_specialtyFramingham Risk Scorebusiness.industryPreventionSmall dense LDLmedicine.diseaseCoronary artery diseaseCoronary heart diseasechemistry.chemical_compoundchemistryCardiovascular preventionRisk factorsLow-density lipoproteinInternal medicineAtherosclerosiInternal MedicinemedicineCardiologylipids (amino acids peptides and proteins)Risk factorbusinessNational Cholesterol Education ProgramLipoprotein
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (&lt;80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active &lt;30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico

2016

Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol -cLDL+cVLDL+c-remmants+Lp(a)- is the real meas…

medicine.medical_specialtyVery low-density lipoproteinHigh risk patientsbusiness.industryCholesterolHypertriglyceridemia030204 cardiovascular system & hematologymedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePostprandialEndocrinologyCardiovascular preventionchemistryInternal medicineNon hdl cholesterolmedicinelipids (amino acids peptides and proteins)Pharmacology (medical)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

2020

Blood GlucoseAmerican diabetes associationmedicine.medical_specialtybusiness.industryLow density lipoprotein cholesterolCardiovascular outcome trials Cardiovascular prevention Cardiovascular risk Diabetes mellitus type 2 Glucose-lowering drugs Therapeutical targets Blood Glucose Humans Hypoglycemic Agents Cardiovascular Diseases Diabetes Mellitus Type 2 Sodium-Glucose Transporter 2 InhibitorsCall to actionProprotein Convertase Subtilisin/Kexin 9Diabetes Mellitus Type 2Cardiovascular preventionCardiovascular DiseasesHumansHypoglycemic AgentsMedicineCardiology and Cardiovascular MedicinebusinessIntensive care medicineSodium-Glucose Transporter 2 InhibitorsGlycated haemoglobin
researchProduct